iScience, Volume 27

Supplemental information

Optical modulation of cell nucleus penetration

and singlet oxygen release

of a switchable platinum complex

Zakaria Ziani, Saioa Cobo, Nathalie Berthet, and Guy Royal

List of Figures, Schemes and Tables

| Scheme S1. Preparation of DHP-Pt ₂ from DHP-Py ₂ | 2 |
|--|----|
| Table S1. Crystal Data and Structure Refinement for DHP-Pt2. | 2 |
| Table S2. IC50 values (μ M) for DHP-Pt ₂ and CPDO ₂ -Pt ₂ platinum complexes and cisplatin | 4 |
| Figure S1. Emission spectrum of DHP-Pt ₂ in degassed CD ₂ Cl ₂ | 3 |
| Figure S2. Phosphorescence band of singlet oxygen | 3 |
| Figure S3. Agarose gel electrophoresis images | 4 |
| Figure S4. Fluorescence intensity profiles | 5 |
| Figure S5. Thermal back isomerization of CPDO2-Pt2 to DHP-Pt2 and ¹ O2 release in tumorous cells | 6 |
| Figure S6. ¹ H-NMR spectra of DHP-Pt ₂ in CD ₂ Cl ₂ | 7 |
| Figure S7. ¹³ C-NMR spectra of DHP-Pt ₂ in CDCl ₃ | 7 |
| Figure S8. Evolution of the ¹ H-NMR spectra of DHP-Pt ₂ during illumination | 8 |
| Figure S9. ¹ H-NMR spectra of CPDO ₂ -Pt ₂ | 9 |
| Figure S10. Mass spectra of DHP-Pt ₂ i | 10 |
| Figure S11. Mass spectra of CPDO ₂ -Pt ₂ | 10 |



Scheme S1. Preparation of DHP-Pt₂ from DHP-Py₂ related to Figure 1.

Table S1. Crystal Data and Structure Refinement for DHP-Pt₂ related to Figure 1.

| Formula | $C_{40}H_{50}Cl_4N_2O_2Pt_2S_2$ |
|--|---------------------------------|
| Fw (g mol ^{−1}) | 1186.92 |
| Crystal system | Monoclinic |
| Space group | P21/c |
| a (Å) | 5.8439(12) |
| b (Å) | 28.182(6) |
| <i>c</i> (Å) | 13.367(3) |
| lpha (deg.) | 90 |
| β (deg.) | 99.61(3) |
| γ(deg.) | 90 |
| V (Å ³) / Z | 2170.6(8) |
| <i>Dx</i> (g cm ⁻³) | 1.816 |
| μ (cm ⁻¹) | 6.816 |
| Crystal dim. (mm) | 0.10 x 0.27 x 0.38 |
| <i>Т</i> (К) | 200 |
| hetarange for coll. (deg.) | 3.091-27.000 |
| nb. of rflns. coll. | 24281 |
| Data/restraints/parameters | 3802/0/241 |
| R (/)ª all/R[I>2σ(I)] | 0.0585/0.0405 |
| Goodness of fit S | 1.122 |
| Δρ _{min} / Δρ _{max} (e Å ⁻³) | -1.047/2.380 |

 ${}^{a}R = \sum ||I_{o}| - |I_{c}|| / \sum |I_{o}|.$



Figure S1. Emission spectrum of **DHP-Pt₂** in degassed CD₂Cl₂ related to Figure 5. Excitation wavelength: 470 nm.



Figure S2. Phosphorescence band of singlet oxygen related to Figure 6.

Phosphorescence band of singlet oxygen characteristic of the deexcitation of the metastable singlet oxygen (${}^{1}O_{2}$) to its triplet ground state (${}^{3}O_{2}$) of a solution of **DHP-Pt**₂ in dichloromethane at 25°C. OD = 0.1.



Figure S3. Agarose gel electrophoresis images

Agarose gel electrophoresis images of pBR322 DNA plasmid (13 μ g.mL⁻¹) incubated for 16h at 37°C with increasing concentrations of *bis*-pyridine **DHP-Py**₂ ligand. Lane 1: pure plasmid DNA; Lanes 2-10: 0.09, 0.19, 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25 μ M of compound related to Figure 3.

Table S2. IC50 values (μ M) for DHP-Pt₂ and CPDO₂-Pt₂ platinum complexes and cisplatin related to Figure 4.

IC50 values (μ M) for **DHP-Pt₂** and **CPDO₂-Pt₂** platinum complexes and cisplatin with A-375, HeLa and HFF-1 cell lines after 24 h, 48 h and 72 h of incubation. Data show means ± SD of three independent experiments.

| | IC₅₀ (μM) | | | | | | | |
|------------------------------------|----------------|----------------|----------------------------------|----------------|----------------|----------------|-------|--|
| | A-375 | | | HeLa | | | HFF-1 | |
| | 24h | 48 h | 72 h | 24h | 48 h | 72 h | 48h | |
| DHP-Pt ₂ | 67.0 ± 6.4 | 52.5 ± 5.4 | $\textbf{45.5} \pm \textbf{3.1}$ | 70.8 ± 7.2 | 59.8 ± 4.9 | 36.3 ± 4.1 | >100 | |
| CPDO ₂ -Pt ₂ | 67.6 ± 7.1 | 56.2 ± 4.8 | 46.1 ± 4.2 | 77.6±6.8 | 61.9 ± 5.2 | 40.0 ± 5.1 | >100 | |
| Cisplatin | 7.2 ± 1.6 | 2.9±0.5 | 2.5 ± 0.8 | 4.5 ± 0.9 | 2.9 ± 0.6 | 2.7 ± 0.6 | Nd. | |

Nd. Stands Not determined



Figure S4. Fluorescence intensity profiles related to Figure 5.

Fluorescence intensity profiles for the both forms of the bis-platinum complex (**DHP-Pt**₂ and **CPDO**₂-**Pt**₂, red) and the nuclear marker Hoechst 33342 (blue) in the cancer cell lines BT-549 and A-375 (right columns). The regions of the images which were analysed are shown with yellow arrows (left columns).



Figure S5. Thermal back isomerization of $CPDO_2$ -Pt₂ to DHP-Pt₂ and ¹O₂ release in tumorous cells related to Figure 6.

Confocal fluorescence microscope images of A-375 cells treated with 10 μ M of **CPDO₂-Pt**₂ for 4h and 24h at 37°C. Imaging of ¹O₂ release from **CPDO₂-Pt**₂ was followed using DCFH-DA as intracellular ROS probe. Scale bars are 20 μ m.

At 4h and 24h a significant DCF fluorescence (green) is observed indicating a ${}^{1}O_{2}$ release from the **CPDO₂-Pt**₂ complex in the tumorous cells. The fluorescence of the DCF observed is globally the same at 4h and 24h, indicating that the ${}^{1}O_{2}$ release step is finished within 4h under our experimental conditions. The increase in **DHP-Pt**₂ fluorescence (in red) between microscopy images at 4 h and 24 h illustrates the thermal back isomerization (at T = 37°C) between the initially non-emissive **CPDO₂-Pt**₂ form and the fluorescent **DHP-Pt**₂ form.



Figure S6. ¹H-NMR spectra of DHP-Pt₂ in CD_2Cl_2 related to Figure 1.



Figure S7. ¹³C-NMR spectra of **DHP-Pt**₂ in CDCl₃ related to Figure 1.



Figure S8. Evolution of the¹H-NMR spectra of DHP-Pt₂ during illumination

Evolution of the¹H-NMR spectra of **DHP-Pt₂** during illumination with visible light ($\lambda > 630$ nm) under aerobic conditions (air, P = 1 atm.). Solvent: CD₂Cl₂ related to Figure 1.



Figure S9. ¹H-NMR spectra of CPDO₂-Pt₂ related to Figure 1.

¹H-NMR spectra of CPDO₂-Pt₂ formed by illumination with red light of a solution of DHP-Pt₂ in CD_2Cl_2 (<5% of DHP-Pt₂ are remaining).



Figure S10. Mass spectra of DHP-Pt₂ related to Figure 1.

Experimental (top) and calculated (down) electrospray ionization mass spectra of $DHP-Pt_2$ in CH_2Cl_2 .



Figure S11. Mass spectra of CPDO₂-Pt₂ related to Figure 1.

Experimental (top) and calculated (down) electrospray ionization mass spectra of $CPDO_2-Pt_2$ in CH_2Cl_2 .